ST Pharm Co.,Ltd. (KOSDAQ:237690)

Market Cap	2.94T +92.9%
Revenue (ttm)	331.68B +21.2%
Net Income	54.99B +58.4%
EPS	2,688.35 +51.1%
Shares Out	20.83M
PE Ratio	52.49
Forward PE	46.26
Dividend	500.00 (0.35%)
Ex-Dividend Date	Mar 30, 2026

Volume	80,192
Average Volume	126,533
Open	141,100
Previous Close	141,100
Day's Range	140,500 - 146,100
52-Week Range	67,400 - 171,500
Beta	0.35
RSI	47.07
Earnings Date	Apr 28, 2026

About ST Pharm

ST Pharm Co.,Ltd., provides manufacturing services for active pharmaceutical ingredient and intermediate. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical research and development solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1983
• Employees: 655
• Stock Exchange: KOSDAQ
• Ticker Symbol: 237690

Financial Performance

In 2025, ST Pharm's revenue was 331.68 billion, an increase of 21.16% compared to the previous year's 273.75 billion. Earnings were 54.99 billion, an increase of 58.42%.